Evaluating Multimodal Ultrasound to Monitor Muscle Mass in Metabolic Syndrome, Type 2 Diabetes, and Obesity

What This Trial Is About

Researchers are evaluating the use of multimodal ultrasound to assess muscle mass in people with metabolic diseases such as metabolic syndrome, type 2 diabetes, and simple obesity. Muscle mass reduction is common in these conditions and is linked to insulin resistance and complications. Current muscle assessment methods like DXA, CT, and MRI have drawbacks including high cost, radiation exposure, or limited portability, making them less suitable for routine use. The study will include 320 participants divided into four groups metabolic syndrome, type 2 diabetes, simple obesity, and healthy controls. Each participant will undergo baseline clinical data collection, biochemical tests, muscle function tests handgrip strength, gait speed, SPPB, multimodal ultrasound examinations measuring muscle morphology, stiffness, microcirculation, and DXA scans as a standard reference. The metabolic disease groups will have follow-up assessments at 6 and 12 months. Participants will be assessed using clinical exams, blood tests, muscle function evaluations, and advanced ultrasound imaging performed by trained sonographers. Researchers will analyze ultrasound parameters to identify diagnostic thresholds for metabolic sarcopenia, correlate these with metabolic indicators, and develop combined diagnostic models. The study will also evaluate how baseline ultrasound findings predict disease progression and complications over 12 months, aiming to provide a convenient, non-invasive tool for muscle assessment in metabolic disease management.

A Clinical Study on Using Multimodal Ultrasound to Assess Muscle Mass in Metabolic Diseases